The FDA is guaranteeing a priority review for Boehringer Ingelheim’s much-watched treatment for a rare lung disease, likely speeding up the drug’s path to market as the German pharma races with biotech InterMune.

…read more

Source: FDA promises a fast review for Boehringer’s lung disease contender


0 No comments